Enliven Therapeutics Stock Forecast

Stock Price Forecast

The 5 analysts that cover Enliven Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $39.6, which forecasts a 101.58% increase in the stock price over the next year. The lowest target is $27 and the highest is $52.

Price Target: $39.6 (+101.58%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$27	$39.6	$40	$52
Change	+37.44%	+101.58%	+103.61%	+164.70%

Analyst Ratings

The average analyst rating for Enliven Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '25	Feb '25	Mar '25	Apr '25	May '25	Jun '25
Strong Buy	4	4	4	4	3	4
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Salveen Richter Goldman Sachs	Goldman Sachs	Strong Buy Initiates $37	Strong Buy	Initiates	$37	+88.34%	Jun 16, 2025
Colleen Kusy Baird	Baird	Buy Maintains $40 → $52	Buy	Maintains	$40 → $52	+164.70%	Jun 16, 2025
Soumit Roy Jones Trading	Jones Trading	Strong Buy Maintains $36 → $27	Strong Buy	Maintains	$36 → $27	+37.44%	May 16, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $39 → $40	Strong Buy	Maintains	$39 → $40	+103.61%	May 15, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $37 → $39	Strong Buy	Maintains	$37 → $39	+98.52%	Mar 21, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 104.17M

Revenue Next Year

n/a

EPS This Year

-2.31

from -1.89

EPS Next Year

-2.67

from -2.31

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	8.50K	7.28K	10.20K	10.20K	104.17M
Revenue Growth	-	-14.29%	40.06%	-	1,021,174.51%	-	-	-
EPS	-3.80	-3.17	-12.05	-2.01	-1.89	-2.31	-2.67	-3.34
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	11	10	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	52,500	52,500	52,500
Avg	8,497	7,283	10,200
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027
High	-99.9%	517.9%	620.9%
Avg	-100.0%	-14.3%	40.1%
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027
High	-2.10	-2.05	-1.86
Avg	-2.31	-2.67	-3.34
Low	-2.54	-3.11	-4.22

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.